Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

Now Viewing

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists address key unmet medical needs in light chain (AL) amyloidosis. They highlight the urgency for early diagnosis, emphasizing awareness and education, especially for distinguishing the disease from multiple myeloma. The discussion stresses the need for specialized care for patients with advanced cardiac involvement who are excluded from current clinical trials.

Another crucial unmet need is the absence of validated criteria for relapsed and refractory cases, leading to uncertainties in reinitiating therapy. Lastly, the speakers emphasize the necessity for licensed antifibril agents to remove amyloid deposits from organs. They suggest exploring various targets in the fibrogenesis pathway for a comprehensive therapeutic approach. They acknowledge the challenge of fully reversing organ damage, particularly in advanced cases, highlighting the intricate nature of treating AL amyloidosis.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.